Trial Profile
A phase II Clinical Trial on the use of ARA 290 for the treatment of Diabetic Macular Oedema
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Oct 2022
Price :
$35
*
At a glance
- Drugs Cibinetide (Primary)
- Indications Diabetic macular oedema
- Focus Proof of concept; Therapeutic Use
- 21 Jul 2020 Results published in the Journal of Clinical Medicine
- 20 Jul 2020 According to an Araim Pharmaceuticals media release, Dr. Noemi Lois is the lead investigator of this study.
- 20 Jul 2020 Results (n=9) presented in an Araim Pharmaceuticals Media Release